Literature DB >> 18211624

Tumor lysis syndrome during treatment with AMN107 (Nilotinib) in a patient with chronic myelogenous leukemia accelerated phase.

M Sonmez, E Ovali, S B Omay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18211624     DOI： 10.1111/j.1365-2710.2008.00873.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN： 0269-4727            Impact factor:   2.512


× No keyword cloud information.
  3 in total

1.  Tumor Lysis Syndrome in the Chronic Phase of Chronic Myeloid Leukemia Following COVID-19 Infection: A Case Report.

Authors:  Adnan Humam Waseem Hajjar; Shahem Abbarh; Abdulrahman Al-Mashdali; Awni Alshurafa; Mohammad Abu-Tineh; Hana Qasim; Khalid Ahmed; Mohamed A Yassin
Journal:  Cureus       Date:  2022-04-22

Review 2.  European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Authors:  J L Steegmann; M Baccarani; M Breccia; L F Casado; V García-Gutiérrez; A Hochhaus; D-W Kim; T D Kim; H J Khoury; P Le Coutre; J Mayer; D Milojkovic; K Porkka; D Rea; G Rosti; S Saussele; R Hehlmann; R E Clark
Journal:  Leukemia       Date:  2016-04-28       Impact factor: 11.528

3.  Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis.

Authors:  Megumi Koshiishi; Yuki Sueki; Ichiro Kawashima; Kei Nakajima; Toru Mitsumori; Keita Kirito
Journal:  Intern Med       Date:  2017-08-10       Impact factor: 1.271
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.